Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 11/2018

01-11-2018 | Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Management of Chronic Prostatitis (CP)

Authors: Nadir Zaidi, Dominique Thomas, Bilal Chughtai

Published in: Current Urology Reports | Issue 11/2018

Login to get access

Abstract

Purpose of Review

To review the most up-to-date diagnosis and treatment of chronic prostatitis. We conducted a review of the literature based on the diagnosis and treatment of chronic prostatitis.

Recent Findings

The use of advanced phenotyping, links to lifestyle, and multimodal approaches has helped to enhance the treatment of chronic prostatitis and its negative effects on quality of life.

Summary

Chronic prostatitis is a common and complex condition that requires a multimodal approach to treat symptoms. Recent advances in phenotyping and risk factors help to individualize treatment and enhance treatment outcomes.
Literature
1.
Krieger JN, Nyberg L, Jr., Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282(3):236–237.CrossRefPubMed
2.
Zhang R, Sutcliffe S, Giovannucci E, Willett WC, Platz EA, Rosner BA, et al. Lifestyle and risk of chronic prostatitis/chronic pelvic pain syndrome in a cohort of United States Male Health Professionals. J Urol. 2015;194(5):1295–300.CrossRefPubMedPubMedCentral
3.
Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol. 1998;159(4):1224–8.CrossRefPubMed
4.
Krieger JN, Lee SWH, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. Int J Antimicrob Agents. 2008;31(Suppl 1):S85–90.CrossRefPubMed
5.
Roberts RO, Lieber MM, Rhodes T, Girman CJ, Bostwick DG, Jacobsen SJ. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County study of urinary symptoms and health status among men. Urology. 1998;51(4):578–84.CrossRefPubMed
6.
7.
Duloy AM, Calhoun EA, Clemens JQ. Economic impact of chronic prostatitis. Curr Urol Rep. 2007;8(4):336–9.CrossRefPubMed
8.
Anderson RU, Wise D, Sawyer T, Chan CA. Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: improvement after trigger point release and paradoxical relaxation training. J Urol. 2006;176(4 Pt 1):1534–8. discussion 1538–1539 CrossRefPubMed
9.
Bowen DK, Dielubanza E, Schaeffer AJ. Chronic bacterial prostatitis and chronic pelvic pain syndrome. BMJ Clin Evid. 2015;2015
10.
Thakkinstian A, Attia J, Anothaisintawee T, Nickel JC. alpha-Blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJU Int 2012;110(7):1014–1022.CrossRefPubMed
11.
Sharp VJ, Takacs EB, Powell CR. Prostatitis: diagnosis and treatment. Am Fam Physician. 2010;82(4):397–406.PubMed
12.
Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis : Off Publ Infect Dis Soc Am. 2010;50(12):1641–52.CrossRef
13.
El Meliegy AI, Torky M. An observational study to monitor the efficacy and tolerability of levofloxacin 500 mg once daily for treatment of chronic bacterial prostatitis in Saudi Arabia. Urol Ann. 2015;7(1):71–3.CrossRefPubMedPubMedCentral
14.
Zhang ZC, Jin FS, Liu DM, Shen ZJ, Sun YH, Guo YL. Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients. Asian J Androl. 2012;14(6):870–4.CrossRefPubMedPubMedCentral
15.
Cai T, Mazzoli S, Addonisio P, Boddi V, Geppetti P, Bartoletti R. Clinical and microbiological efficacy of prulifloxacin for the treatment of chronic bacterial prostatitis due to Chlamydia trachomatis infection: results from a prospective, randomized and open-label study. Methods Find Exp Clin Pharmacol. 2010;32(1):39–45.CrossRefPubMed
16.
Busetto GM, Giovannone R, Ferro M, Tricarico S, del Giudice F, Matei DV, et al. Chronic bacterial prostatitis: efficacy of short-lasting antibiotic therapy with prulifloxacin (Unidrox®) in association with saw palmetto extract, lactobacillus sporogens and arbutin (Lactorepens®). BMC Urol. 2014;14:53.CrossRefPubMedPubMedCentral
17.
•• Bartoletti R, Cai T, Nesi G, et al. The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort study. World J Urol. 2014;32(3):737–42. Patients with chronic bacterial prostatitis found to have biofilm-producting bacteria are less likely to experience improvement in symptoms after fluoroquinolone treatment than patients without biofilm-producing bacteria CrossRefPubMed
18.
Nickel JC. Treatment of chronic prostatitis/chronic pelvic pain syndrome. Int J Antimicrob Agents. 2008;31(Supplement 1):112–6.CrossRefPubMedCentral
19.
Wagenlehner FM, van Till JW, Magri V, et al. National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome. Eur Urol. 2013;63(5):953–9.CrossRefPubMed
20.
Zhao Z, Zhang J, He J, Zeng G. Clinical utility of the UPOINT phenotype system in Chinese males with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a prospective study. PLoS One. 2013;8(1):e52044.CrossRefPubMedPubMedCentral
21.
•• Davis SN, Binik YM, Amsel R, Carrier S. Is a sexual dysfunction domain important for quality of life in men with urological chronic pelvic pain syndrome? Signs “UPOINT” to yes. J Urol. 2013;189(1):146–51. The two domains from UPOINTs that most strongly predicted quality of life were the psychosocial and sexual dysfunction domains. This study provided support for adding a sexual dysfunction domain to the UPOINT phenotyping system. CrossRefPubMed
22.
Gallo L. Effectiveness of diet, sexual habits and lifestyle modifications on treatment of chronic pelvic pain syndrome. Prostate Cancer Prostatic Dis. 2014;17(3):238–45.CrossRefPubMed
23.
Zhang R, Chomistek AK, Dimitrakoff JD, et al. Physical activity and chronic prostatitis/chronic pelvic pain syndrome. Med Sci Sports Exerc. 2015;47(4):757–64.CrossRefPubMedPubMedCentral
24.
Tripp DA, Nickel JC, Shoskes D, Koljuskov A. A 2-year follow-up of quality of life, pain, and psychosocial factors in patients with chronic prostatitis/chronic pelvic pain syndrome and their spouses. World J Urol. 2013;31(4):733–9.CrossRefPubMed
25.
Koh JS, Ko HJ, Wang SM, Cho KJ, Kim JC, Lee SJ, et al. Depression and somatic symptoms may influence on chronic prostatitis/chronic pelvic pain syndrome: a preliminary study. Psychiatry Investig. 2014;11(4):495–8.CrossRefPubMedPubMedCentral
26.
Wagenlehner FM, Ballarini S, Naber KG. Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one-year prospective, double-blind, placebo-controlled study. World J Urol. 2014;32(6):1595–603.CrossRefPubMed
27.
Wagenlehner FME, van Till JWO, Houbiers JGA, Martina RV, Cerneus DP, Melis JHJM, et al. Fatty acid amide hydrolase inhibitor treatment in men with chronic prostatitis/chronic pelvic pain syndrome: an adaptive double-blind, randomized controlled trial. Urology. 2017;103:191–7.CrossRefPubMed
28.
Nickel JC, Atkinson G, Krieger JN, Mills IW, Pontari M, Shoskes DA, et al. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2012;80(5):1105–10.CrossRefPubMed
29.
Nickel JC, O'Leary MP, Lepor H, Caramelli KE, Thomas H, Hill LA, et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study. J Urol. 2011;186(1):125–31.CrossRefPubMed
30.
Giannantoni A, Porena M, Gubbiotti M, Maddonni S, Di Stasi SM. The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2014;83(2):400–5.CrossRefPubMed
31.
Choe HS, Lee SJ, Han CH, Shim BS, Cho YH. Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. J Infect Chemother : Off J Japan Soc Chemother. 2014;20(1):20–5.CrossRef
32.
Pontari MA, Krieger JN, Litwin MS, White PC, Anderson RU, McNaughton-Collins M, et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Arch Intern Med. 2010;170(17):1586–93.CrossRefPubMedPubMedCentral
33.
Agarwal MM, Elsi Sy M. Gabapentenoids in pain management in urological chronic pelvic pain syndrome: gabapentin or pregabalin? Neurourol Urodyn. 2017;36(8):2028–33.CrossRefPubMed
34.
Kong do H, Yun CJ, Park HJ, Park NC. The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle-aged males. World J Men Health. 2014;32(3):145–50.CrossRef
35.
Magri V, Marras E, Restelli A, Wagenlehner FM, Perletti G. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Exp Ther Med. 2015;9(3):658–66.CrossRefPubMed
36.
•• Sahin S, Bicer M, Eren GA, et al. Acupuncture relieves symptoms in chronic prostatitis/chronic pelvic pain syndrome: a randomized, sham-controlled trial. Prostate Cancer Prostatic Dis. 2015;18(3):249–54. Patients with CP/CPPS who receieved acupuncture experienced a reduction in NIH-CPSI score that was statistically significant compared to patients who received sham therapy CrossRefPubMed
37.
Kucuk EV, Suceken FY, Bindayi A, Boylu U, Onol FF, Gumus E. Effectiveness of acupuncture on chronic prostatitis-chronic pelvic pain syndrome category IIIB patients: a prospective, randomized, nonblinded, clinical trial. Urology. 2015;85(3):636–40.CrossRefPubMed
38.
•• Falahatkar S, Shahab E, Gholamjani Moghaddam K, Kazemnezhad E. Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double-blind and randomized placebo-controlled study. British Journal of Urology International. 2015;116(4):641–9. Patients with CP/CPPS who received botulinum toxin experienced a statistically significant reduction in NIH-CPSI score from their baseline status CrossRef
39.
Abdel-Meguid TA, Mosli HA, Farsi H, Alsayyad A, Tayib A, Sait M, et al. Treatment of refractory category III nonbacterial chronic prostatitis/chronic pelvic pain syndrome with intraprostatic injection of onabotulinum toxin A: a prospective controlled study. Can J Urol. 2018;25(2):9273–80.PubMed
40.
Li HS, Wang B, Han L, Wang CH, Xin ZC. Transperineal ultrasonic therapy for chronic prostatitis. Zhonghua nan ke xue = Natl J Androl. 2013;19(1):49–53.
41.
Kessler TM, Mordasini L, Weisstanner C, Jüni P, da Costa BR, Wiest R, et al. Sono-electro-magnetic therapy for treating chronic pelvic pain syndrome in men: a randomized, placebo-controlled, double-blind trial. PLoS One. 2014;9(12):e113368.CrossRefPubMedPubMedCentral
42.
Moayednia A, Haghdani S, Khosrawi S, Yousefi E, Vahdatpour B. Long-term effect of extracorporeal shock wave therapy on the treatment of chronic pelvic pain syndrome due to non bacterial prostatitis. J Res Med Sci : Off J Isfahan Univ Med Sci. 2014;19(4):293–6.
43.
Pajovic B, Radojevic N, Dimitrovski A, Vukovic M. Comparison of the efficiency of combined extracorporeal shock-wave therapy and triple therapy versus triple therapy itself in Category III B chronic pelvic pain syndrome (CPPS). The Aging Male : The Official Journal of the International Society for the Study of the Aging Male. 2016;19(3):202–7.CrossRef
Metadata
Title
Management of Chronic Prostatitis (CP)
Authors
Nadir Zaidi
Dominique Thomas
Bilal Chughtai
Publication date
01-11-2018
Publisher
Springer US
Published in
Current Urology Reports / Issue 11/2018
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-018-0841-9

Other articles of this Issue 11/2018

Current Urology Reports 11/2018 Go to the issue

New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Advanced Imaging for the Diagnosis and Treatment of Coexistent Renal and Müllerian Abnormalities

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection?

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder

New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Use of MR Urography in Pediatric Patients

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Complications of Botox and their Management

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Management of Overactive Bladder in Older Women